<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font20 { font-size : 20; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font25">and </span>
   <span class="font20">for </span>
   <span class="font17">clinical </span>
   <span class="font17">respiratory </span>
   <span class="font17">with </span>
   <span class="font14">COVID- </span>
   <span class="font13">case </span>
   <span class="font13">{background </span>
   <span class="font12">margin </span>
   <span class="font12">treatment </span>
   <span class="font12">{border-style </span>
   <span class="font12">px;} </span>
   <span class="font12">tablets, </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">during </span>
   <span class="font12">infection </span>
   <span class="font12">severe </span>
   <span class="font12">coronavirus </span>
   <span class="font12">daily </span>
   <span class="font12">has </span>
   <span class="font12">not </span>
   <span class="font12">should </span>
   <span class="font12">tablet </span>
   <span class="font11">SARS-CoV- </span>
   <span class="font11">The </span>
   <span class="font11">blood </span>
   <span class="font11">chloroquine </span>
   <span class="font11">days </span>
   <span class="font11">patients </span>
   <span class="font11">performed </span>
   <span class="font11">(e.g. </span>
   <span class="font11">and/or </span>
   <span class="font11">lung </span>
   <span class="font11">ARDS </span>
   <span class="font11">Available </span>
   <span class="font11">affected </span>
   <span class="font11">are </span>
   <span class="font11">been </span>
   <span class="font11">days, </span>
   <span class="font11">hours </span>
   <span class="font11">symptoms </span>
   <span class="font11">worsening </span>
   <span class="font11">&amp;lt; </span>
   <span class="font11">TCZ </span>
   <span class="font11">care </span>
   <span class="font11">collab: </span>
   <span class="font11">failure </span>
   <span class="font11">from </span>
   <span class="font11">novel </span>
   <span class="font11">possible </span>
   <span class="font11">February </span>
   <span class="font11">after </span>
   <span class="font11">antiviral </span>
   <span class="font11">based </span>
   <span class="font11">data </span>
   <span class="font11">detection </span>
   <span class="font11">disease </span>
   <span class="font11">followed </span>
   <span class="font11">intensive </span>
   <span class="font11">management </span>
   <span class="font11">signs </span>
   <span class="font11">viral </span>
   <span class="font11">Chest </span>
   <span class="font11">National </span>
   <span class="font11">acute </span>
   <span class="font11">available </span>
   <span class="font11">dose </span>
   <span class="font11">efficacy </span>
   <span class="font11">gas </span>
   <span class="font11">levels </span>
   <span class="font11">lopinavir/ritonavir </span>
   <span class="font11">monitoring: </span>
   <span class="font11">px; </span>
   <span class="font11">remdesivir </span>
   <span class="font11">rhinopharyngeal </span>
   <span class="font11">swab </span>
   <span class="font11">therapy: </span>
   <span class="font11">which </span>
   <span class="font11">within </span>
   <span class="font11">without </span>
   <span class="font11">{font-family </span>
   <span class="font10">China </span>
   <span class="font10">Clinical </span>
   <span class="font10">Feb </span>
   <span class="font10">Health </span>
   <span class="font10">before </span>
   <span class="font10">charge </span>
   <span class="font10">diagnostics: </span>
   <span class="font10">dose, </span>
   <span class="font10">font-size </span>
   <span class="font10">intravenously </span>
   <span class="font10">mmHg </span>
   <span class="font10">monitoring </span>
   <span class="font10">new </span>
   <span class="font10">patient </span>
   <span class="font10">perform </span>
   <span class="font10">rapid </span>
   <span class="font10">rate, </span>
   <span class="font10">single </span>
   <span class="font10">specialist </span>
   <span class="font10">syndrome </span>
   <span class="font10">therapy </span>
   <span class="font10">use </span>
   <span class="font10">&amp;gt; </span>
   <span class="font10">China. </span>
   <span class="font10">Chloroquine </span>
   <span class="font10">IL- </span>
   <span class="font10">Infectious </span>
   <span class="font10">PCR </span>
   <span class="font10">Remdesivir </span>
   <span class="font10">Severe </span>
   <span class="font10">Tocilizumab </span>
   <span class="font10">according </span>
   <span class="font10">administration </span>
   <span class="font10">agents </span>
   <span class="font10">availability </span>
   <span class="font10">critical </span>
   <span class="font10">doi: </span>
   <span class="font10">double; </span>
   <span class="font10">every </span>
   <span class="font10">first </span>
   <span class="font10">have </span>
   <span class="font10">higher </span>
   <span class="font10">may </span>
   <span class="font10">order </span>
   <span class="font10">this </span>
   <span class="font10">"L. </span>
   <span class="font10">Acute </span>
   <span class="font10">Antiviral </span>
   <span class="font10">Coronavirus </span>
   <span class="font10">Disease </span>
   <span class="font10">European </span>
   <span class="font10">HIV </span>
   <span class="font10">Infect </span>
   <span class="font10">Institute </span>
   <span class="font10">Italy </span>
   <span class="font10">MEWS </span>
   <span class="font10">March </span>
   <span class="font10">Med </span>
   <span class="font10">PaO/FiO </span>
   <span class="font10">RT-PCR </span>
   <span class="font10">Treatment </span>
   <span class="font10">adverse </span>
   <span class="font10">against </span>
   <span class="font10">antigen </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cases </span>
   <span class="font10">conditions </span>
   <span class="font10">distress </span>
   <span class="font10">drug </span>
   <span class="font10">drugs </span>
   <span class="font10">evaluated </span>
   <span class="font10">following </span>
   <span class="font10">high </span>
   <span class="font10">hospital </span>
   <span class="font10">increase </span>
   <span class="font10">infection. </span>
   <span class="font10">interactions </span>
   <span class="font10">least </span>
   <span class="font10">loading </span>
   <span class="font10">only </span>
   <span class="font10">parameters </span>
   <span class="font10">phosphate </span>
   <span class="font10">recent </span>
   <span class="font10">response </span>
   <span class="font10">risk </span>
   <span class="font10">sample </span>
   <span class="font10">score </span>
   <span class="font10">solid; </span>
   <span class="font10">starting </span>
   <span class="font10">suspected </span>
   <span class="font10">that </span>
   <span class="font10">therapeutic </span>
   <span class="font10">together </span>
   <span class="font10">virus </span>
   <span class="font10">visited </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(if </span>
   <span class="font10">(once/work </span>
   <span class="font10">Additional </span>
   <span class="font10">Berlin </span>
   <span class="font10">Characteristics: </span>
   <span class="font10">Chinese </span>
   <span class="font10">D-dimer, </span>
   <span class="font10">Dosage </span>
   <span class="font10">GPD </span>
   <span class="font10">Hydroxychloroquine </span>
   <span class="font10">Influenza </span>
   <span class="font10">OSI </span>
   <span class="font10">Oxygenation </span>
   <span class="font10">Patient </span>
   <span class="font10">Patients </span>
   <span class="font10">Periodic </span>
   <span class="font10">Prevention </span>
   <span class="font10">SARS-COV </span>
   <span class="font10">Strict </span>
   <span class="font10">Supportive </span>
   <span class="font10">Use </span>
   <span class="font10">action </span>
   <span class="font10">aimed </span>
   <span class="font10">antimicrobial </span>
   <span class="font10">assessment </span>
   <span class="font10">bold </span>
   <span class="font10">both </span>
   <span class="font10">combination </span>
   <span class="font10">confirmed </span>
   <span class="font10">count </span>
   <span class="font10">courier; </span>
   <span class="font10">currently </span>
   <span class="font10">days. </span>
   <span class="font10">declared </span>
   <span class="font10">definition </span>
   <span class="font10">demonstrated </span>
   <span class="font10">described </span>
   <span class="font10">due </span>
   <span class="font10">early </span>
   <span class="font10">em; </span>
   <span class="font10">exchange </span>
   <span class="font10">expert </span>
   <span class="font10">failure, </span>
   <span class="font10">fever </span>
   <span class="font10">goals </span>
   <span class="font10">heart </span>
   <span class="font10">improvement </span>
   <span class="font10">in-vitro </span>
   <span class="font10">inflammatory </span>
   <span class="font10">inhibiting </span>
   <span class="font10">involvement. </span>
   <span class="font10">limited </span>
   <span class="font10">lower </span>
   <span class="font10">microbiologic </span>
   <span class="font10">mild </span>
   <span class="font10">moderate </span>
   <span class="font10">multiplex </span>
   <span class="font10">negative </span>
   <span class="font10">one </span>
   <span class="font10">other </span>
   <span class="font10">persistently </span>
   <span class="font10">person </span>
   <span class="font10">pneumonia </span>
   <span class="font10">pneumonia. </span>
   <span class="font10">presenting </span>
   <span class="font10">procedures </span>
   <span class="font10">pt;} </span>
   <span class="font10">pulmonary </span>
   <span class="font10">radiological </span>
   <span class="font10">recommended </span>
   <span class="font10">release </span>
   <span class="font10">required </span>
   <span class="font10">samples </span>
   <span class="font10">second </span>
   <span class="font10">serology </span>
   <span class="font10">specific </span>
   <span class="font10">stage </span>
   <span class="font10">suggesting </span>
   <span class="font10">test </span>
   <span class="font10">tract </span>
   <span class="font10">trials </span>
   <span class="font10">until </span>
   <span class="font10">using </span>
   <span class="font10">vital </span>
  </p>
 </body>
</html>
